Leucine amino peptidase (LAP) activity was studied in serum and urine samples of 25 healthy ambulant subjects, 20 patients with Iocalised and 41 patients with malignant disseminated disease. Serum levels of the enzyme were elevated but not significantly in both Iocalised and disseminated disease whereas the urinary activity of the enzyme was markedly elevated in disseminated disease (p < 0.001) as compared to Iocalised disease. This quantitative method used for determination is reliable, accurate, simple, rapid and cost effective and therefore has better application as an indicator of disseminated disease in a clinical setting.
INTRODUCTION
Leucine amino peptidase (LAP) a proteolytic enzyme is widely distributed in bacteda, plants and animals with high activity in duodenum, kidney and liver.
LAP has sensitivity and diagnostic significance. Elevated LAP activity in serum usually indicates diseases of liver and bile ducts (1) (2) (3) (4) (5) and this elevation is less affected by damage of liver parenchyma than by active participation of biliary tract in the process (6) . LAP can also be used as a marker in testicular tumors (7) .
OBJECTIVE
The objective of the present communication is to determine whether a correlation exists between the enzyme LAP and the clinical findings in patients with malignant disease, and if it fulfils the general agreement of clinicians on the need for more specific biochemical aid in diagnosis and evaluation of malignant disease as the activity of the enzyme is closely related to the pathologic tumor growth.
MATERIALS AND METHODS
Serum and random urine samples of 25 healthy ambulant subjects, 20 patients with Iocalised neoplasm and 41 patients with disseminated disease with histologically proven carcinoma of different sites like head and neck, gastrointestinal tract, lung were included in the study. All cases studied belonged to the age group of 25-60 years. Age and sex distribution were similar between control and study group.
Care was taken to see that none of the cases studied has : 9 hemolytic disorder, renal infarct or renal disease.
9 samples collected were analyzed on the same day.
9 none of the samples were haemolysed.
Quality control sera were run during analysis to check precision and accuracy of the estimation.
LAP was determined by the optimized kinetic method (8) using p-nitroanilide as substrate according to the recommendations of the German Society of Clinical Chemistry. Measurement of creatinine was carried out by the kinetic method without deproteinization (9) .
Measurement of creatinine and LAP were carried out on a fully automated, discrete, random access analyzer Hitachi 705. Urinary activity of the enzyme was expressed as U/g of creatinine. Student 't' test for unpaired numbers was used for statistical analysis after confirming homogeneity of variances.
RESULTS AND DISCUSSION
The results of the expedment are tabulated in Table  1 and 2.
On compa;ring the mean levels of serum LAP activity of the normals with patients with Iocalised and disseminated tumors it was found that the activity of the enzyme was elevated but not significantly. The activity of the enzyme in random urine samples of normals when compared with patients with Iocalised and disseminated tumors it was found that Iocalised tumors did not show any increase whereas disseminated tumors showed a significant increase (p < 0.001) Table 1 .
Localised tumors when compared with disseminated disease it was found that serum levels of the enzyme did not show any increase but the urinary activity of the enzyme in the disseminated disease was significantly elevated (p < 0.001) 4.023 times which is in confirmation with the findings of Phillips eta/. (10). Table 2 gives the frequency of elevation of serum LAP and urinary LAP in pa;tients with Iocalised and disseminated tumors In Iocalised tumors, serum LAP showed a rise in 15 of-the 20 cases (75%) whereas the urinary LAP was raised in 5 of the 20 cases (25%).
In disseminated tumors, serum LAP showed a rise in 31 of the 41 cases (75.6%) whereas the urinary LAP was elevated in all the 41 cases (100%).
Rise in the urinary activity of LAP was found in disseminated diseases and not in Iocalised disease which could be due to glomerular filtration or by renal tubular secretion. The value of determining urine LAP in malignant disease would seem to be an aid in estimating the extent of tumor (10) . Rutenberg et al. (11) observed significantly elevated levels of urinary and serum LAP in patients with malignant lymphoma or leukemia had increased urinary activity but normal or slightly elevated serum levels. Hoffman (12) observed serum activity in patients with benign diseases and normal in patients with carcimoma.
CONCLUSION
Thus our study reveals that this simple, reliable, quick and cost effective analysis of urinary LAP is a better indicator of disseminated diseases.
